[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012014190A2 - composição farmacêutica para o tratamento da síndrome do olho seco - Google Patents

composição farmacêutica para o tratamento da síndrome do olho seco

Info

Publication number
BR112012014190A2
BR112012014190A2 BR112012014190A BR112012014190A BR112012014190A2 BR 112012014190 A2 BR112012014190 A2 BR 112012014190A2 BR 112012014190 A BR112012014190 A BR 112012014190A BR 112012014190 A BR112012014190 A BR 112012014190A BR 112012014190 A2 BR112012014190 A2 BR 112012014190A2
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical composition
dry eye
eye syndrome
compositions
Prior art date
Application number
BR112012014190A
Other languages
English (en)
Other versions
BR112012014190B1 (pt
BR112012014190B8 (pt
Inventor
Bastian Theisinger
Bernhard Günther
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012014190(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Priority to BR122020020872-4A priority Critical patent/BR122020020872B1/pt
Priority to BR122017018955-7A priority patent/BR122017018955B1/pt
Publication of BR112012014190A2 publication Critical patent/BR112012014190A2/pt
Publication of BR112012014190B1 publication Critical patent/BR112012014190B1/pt
Publication of BR112012014190B8 publication Critical patent/BR112012014190B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica para o tratamento da síndrome do olho seco. a invenção seca novas composições farmacêuticas para o tratamento da ceratoconjuntivite seca que compreende os veículos líquidos que incluem um ou mais alcanos semifluorinatados. as composições incorporam um ingrediente ativo selecionado do grupo de imunossupressores macrólidos. podem ser administrados topicamente no olho. a invenção ainda fornece os kits que compreendem tais composições.
BR112012014190A 2009-12-14 2010-12-13 composição farmacêutica para o tratamento da síndrome do olho seco BR112012014190B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122020020872-4A BR122020020872B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco
BR122017018955-7A BR122017018955B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423.8 2009-12-14
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (3)

Publication Number Publication Date
BR112012014190A2 true BR112012014190A2 (pt) 2016-05-31
BR112012014190B1 BR112012014190B1 (pt) 2021-03-02
BR112012014190B8 BR112012014190B8 (pt) 2021-05-25

Family

ID=41731659

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112012014190A BR112012014190B8 (pt) 2009-12-14 2010-12-13 composição farmacêutica para o tratamento da síndrome do olho seco
BR122017018955-7A BR122017018955B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco
BR122020020872-4A BR122020020872B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122017018955-7A BR122017018955B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco
BR122020020872-4A BR122020020872B1 (pt) 2009-12-14 2010-12-13 Composição farmacêutica para o tratamento da síndrome do olho seco

Country Status (16)

Country Link
US (1) US8614178B2 (pt)
EP (2) EP2335735A1 (pt)
JP (5) JP5663595B2 (pt)
KR (2) KR101722039B1 (pt)
CN (1) CN102652022B (pt)
AU (1) AU2010333039B2 (pt)
BR (3) BR112012014190B8 (pt)
CA (2) CA2941956C (pt)
DK (1) DK2512515T3 (pt)
ES (1) ES2449308T3 (pt)
HK (1) HK1172269A1 (pt)
IN (1) IN2012DN03128A (pt)
MX (1) MX2012006720A (pt)
PL (1) PL2512515T3 (pt)
PT (1) PT2512515E (pt)
WO (1) WO2011073134A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
KR101790388B1 (ko) 2011-05-25 2017-10-25 노바리크 게엠베하 부분불소화된 알칸에 기초된 국소 제약학적 조성물
MX361681B (es) 2012-01-23 2018-12-13 Novaliq Gmbh Composiciones de proteína estabilizadas basadas en alcanos semifluorados.
ES2974663T3 (es) * 2012-09-12 2024-07-01 Novaliq Gmbh Alcanos semifluorados para uso en la solubilización de meibomio
DK2708228T3 (en) 2012-09-12 2018-08-20 Novaliq Gmbh COMPOSITION FOR EYE RINSE
US9770508B2 (en) * 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
KR102175622B1 (ko) 2013-03-13 2020-11-06 산텐 세이야꾸 가부시키가이샤 마이봄 기능부전의 치료제
AU2014295052B2 (en) * 2013-07-23 2018-08-30 Novaliq Gmbh Stabilized antibody compositions
AU2014334636A1 (en) * 2013-10-15 2016-06-02 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
DK3495023T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh Semifluorerede forbindelser og sammensætninger deraf
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
US20190343793A1 (en) * 2016-09-28 2019-11-14 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
CN110267645A (zh) * 2016-12-23 2019-09-20 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
US11273174B2 (en) 2017-04-21 2022-03-15 Novaliq Gmbh Iodine compositions
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
IL273531B2 (en) 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CN112135603B (zh) 2018-03-02 2024-04-16 诺瓦利克有限责任公司 包含奈必洛尔的药物组合物
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
WO2020058504A1 (en) 2018-09-22 2020-03-26 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
WO2020239646A1 (en) 2019-05-24 2020-12-03 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
US20210308154A1 (en) 2020-03-24 2021-10-07 Hovione Scientia Limited Methods and Compositions for Treating Meibomian Gland Dysfunction
WO2024170514A1 (en) * 2023-02-13 2024-08-22 Novaliq Gmbh Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
BR0011225A (pt) * 1999-04-30 2002-03-19 Sucampo Ag Agente para tratar de olhos secos, seu método e uso
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
CA2563544A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
CA2569726A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
BR122017018955B1 (pt) 2022-03-08
CA2776860A1 (en) 2011-06-23
WO2011073134A1 (en) 2011-06-23
JP5663595B2 (ja) 2015-02-04
EP2335735A1 (en) 2011-06-22
IN2012DN03128A (pt) 2015-09-18
CN102652022B (zh) 2014-12-17
CA2941956C (en) 2018-09-04
BR112012014190B1 (pt) 2021-03-02
BR122020020872B1 (pt) 2021-09-08
PT2512515E (pt) 2014-03-04
JP6731039B2 (ja) 2020-07-29
KR101652714B1 (ko) 2016-09-01
KR20120115977A (ko) 2012-10-19
US8614178B2 (en) 2013-12-24
JP2017078086A (ja) 2017-04-27
JP2013513586A (ja) 2013-04-22
JP2019070003A (ja) 2019-05-09
JP2015028064A (ja) 2015-02-12
JP6397472B2 (ja) 2018-09-26
CA2941956A1 (en) 2011-06-23
CN102652022A (zh) 2012-08-29
KR101722039B1 (ko) 2017-03-31
JP6096731B2 (ja) 2017-03-15
US20120244177A1 (en) 2012-09-27
MX2012006720A (es) 2012-07-30
AU2010333039A1 (en) 2012-07-12
EP2512515B1 (en) 2013-12-25
DK2512515T3 (en) 2014-03-10
ES2449308T3 (es) 2014-03-19
KR20160105533A (ko) 2016-09-06
HK1172269A1 (en) 2013-04-19
JP2019006803A (ja) 2019-01-17
PL2512515T3 (pl) 2014-05-30
AU2010333039B2 (en) 2014-08-28
CA2776860C (en) 2016-10-25
EP2512515A1 (en) 2012-10-24
BR112012014190B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BR112012014190A2 (pt) composição farmacêutica para o tratamento da síndrome do olho seco
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112019009529A2 (pt) novos derivados de quinolina
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112018075992A2 (pt) piridinas substituídas como inibidores da dnmt1
CU20130033A7 (es) Imidazopiridazinas sustituidas
BRPI0911243B8 (pt) derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112015004997A2 (pt) composições contendo misturas de alcanos semifluorados
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112018013820A2 (pt) análogos de egf(a) com substituintes de ácido graxo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF